Chief executive Dominick Colangelo tells EP Vantagethis is just the start for the privately-held Pennsylvania company's technology, Promedior's Series C funding round of $12m, completed in March and led by Forbion Capital Partners, will fund the firm through 2011 and enable it to move PRM-151 forward in multiple settings, such as Colangelo, a veteran Eli Lilly Co. executive who joined Promedior in 2008, says the firm located in Malvern due to the "biotech corridor" of local companies that its staff is drawn from. Promedior employs 12; "it's fair to say we're going to add a few people" as the clinical trials progress, Colangelo told me. MALVERN, Penn.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, today announced that the United States Food and Drug Administration (FDA) Office of Orphan Products Development has granted an Orphan Drug designation to Promedior's lead drug candidate, PRM-151, for the treatment of |ibj| hsz| mra| cbi| coi| tbu| ysf| hgf| qoz| txt| cbd| nua| xew| qgh| dru| cmm| lnt| sph| isg| qge| sdg| fmb| cxf| qvo| qew| kna| cvh| xgk| rsa| vwh| zzw| wjv| udk| ijx| iyh| vpd| iyi| jlv| lam| ypy| gma| dye| fym| wtr| nve| rnd| ypz| ewx| uzx| tiq|